Markets:

Overview

News

Currencies

International

Treasuries

BioNTech SE - American Depositary Shares (NQ:BNTX)

99.85 +1.00 (+1.01%)

Streaming Delayed Price Updated: 4:00 PM EST, Jan 9, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about BioNTech SE - American Depositary Shares

< Previous 1 2

...

23 24 25 26 27 28 29 30 31

...

71 72 Next >

Is Novavax Stock a Buy Now? ↗

November 26, 2022

There's probably not much good news coming for this biotech in the near future.

Via The Motley Fool

European Official Says COVID-19 Booster Uptake Disappointing In The Region ↗

November 25, 2022

Marco Cavaleri, the European Medicines Agency's (EMA) head of health threats and vaccines strategy, said the recent uptake of COVID-19 vaccine booster doses in the region has been "rather...

Via Benzinga

Researchers Working On Universal mRNA-Influenza Vaccine Aiming For Baseline Immune Memory For Diverse Strains ↗

November 25, 2022

Researchers are working on an experimental pan-influenza vaccine based on the famed mRNA technology to provide broad protection.

Via Benzinga

Is Now the Time for Income Investors to Buy This Big Pharma Stock? ↗

November 24, 2022

This drugmaker is among the most dominant pharmaceutical companies in the world.

Via The Motley Fool

This COVID-19 Vaccine Stock Has More to Offer ↗

November 10, 2022

The vaccine revenue was nice, but it's time to look ahead.

Via The Motley Fool

7 Stocks on the Perfect 10 List ↗

November 23, 2022

Companies that have strong quality, value, or growth grades are the stocks to buy once markets recognize their business potential.

Via InvestorPlace

PFE Stock Could Be the Booster Shot Your Portfolio Needs Now ↗

November 23, 2022

PFE stock still remains a dirt-cheap dividend darling, even after across-the-board earnings beats and lifted guidance.

Via InvestorPlace

Jim Cramer Says China's Vaccines 'Don't Work' But Xi Won't Admit It ↗

November 22, 2022

COVID-19 cases have spiked again in China, sparking fresh lockdown measures in the nation's capital. Jim Cramer has suggested that Chinese President Xi Jinping isn't telling the whole story.

Via Benzinga

2 Reasons to Buy Pfizer and 1 Reason to Sell ↗

November 20, 2022

The pharmaceutical company is looking for a future beyond COVID-19 therapies.

Via The Motley Fool

After Bill Gates Dumps Billions In Berkshire To Buy Microsoft, His Quiet Biotech Portfolio Has Made A New Trade ↗

November 18, 2022

Bill Gates has two portfolios he makes trades from: the Bill & Melinda Gates Foundation and the Bill & Melinda Gates Foundation Trust.

Via Benzinga

7 Stocks to Sell Right Now… and 1 to Buy ↗

November 18, 2022

Although red ink can sometimes bring an opportunity for contrarianism, these (except one) market ideas represent stocks to sell.

Via InvestorPlace

Pfizer/BioNTech's Omicron Tailored COVID-19 Vaccine Shows Improved Immune Response Against Emerging Omicron Sublineages ↗

November 18, 2022

Via Benzinga

Market Rally Holds Key Levels, But Breakouts Struggle; Walmart, Target, Nvidia In Focus: Weekly Review ↗

November 18, 2022

Walmart, Target and Nvidia were key earnings movers.

Via Investor's Business Daily

Pfizer and BioNTech Report New Data on Omicron BA.4/BA.5-Adapted Bivalent Booster Demonstrating Improved Immune Response Against Emerging Omicron Sublineages

November 18, 2022

From BioNTech SE

Via GlobeNewswire

Pfizer, BioNTech Take Next Step Toward A Pan-Covid Vaccine — But Is The Demand There? ↗

November 17, 2022

The biggest question facing the shot is whether there will be demand for it.

Via Investor's Business Daily

Ukraine Asserts It Does Not Take Blame For Poland Missile Attack, Crypto Exchange Gemini Suffers $485M In Outflows, FTX, Bahamas Regulator Lock Horns Over Control Of Bankruptcy Proceedings: Top Stories Thursday, Nov. 17 ↗

November 17, 2022

CNBC

Via Benzinga

Pfizer, BioNTech Start Work On Next-Gen COVID-19 Vaccine Candidate For Broader Protection ↗

November 17, 2022

Via Benzinga

Pfizer and BioNTech Advance Next-Generation COVID-19 Vaccine Strategy with Study Start of Candidate Aimed at Enhancing Breadth of T cell Responses and Duration of Protection

November 16, 2022

From BioNTech SE

Via GlobeNewswire

While COVID-19 Drags On, Biotechs Introduce New Treatments & Vaccines to Combat Subvariants

November 16, 2022

EQNX::TICKER_START (OTCQB:BIXT),(NASDAQ:NVAX),(NYSE:PFE),(NASDAQ:MRNA),(NASDAQ:INO),(NASDAQ:BNTX) EQNX::TICKER_END

Via FinancialNewsMedia

Third COVID-19 Booster or Fifth Dose Not Required Despite Surge In Cases, Australian Health Authorities Say ↗

November 15, 2022

Australian health authorities have recommended against a fifth COVID-19 vaccine shot despite average daily cases having been 47% higher last week than the week before, said Health Minister Mark Butler...

Via Benzinga

Moderna Surges On New Omicron Data, Pulling Pfizer, BioNTech Along For The Ride ↗

November 14, 2022

Its booster led to a 15.1-fold increase in BA.4- and BA.5-blocking antibodies.

Via Investor's Business Daily

Biotech Sector Gaining Wins Against Pancreatic Cancer with Early Detection and New Therapies

November 14, 2022

FN Media Group Presents USA News Group News Commentary Vancouver, BC –November 14, 2022 – USA News Group – English actor, comedian and Monty Python alumnus Eric Idle credits early detection for his...

Via FinancialNewsMedia

BioNTech Plans To Set Up Singapore Based mRNA Plant By End Of 2023 ↗

November 14, 2022

Via Benzinga

BioNTech Expands Global Footprint by Acquiring GMP Manufacturing Site to Establish First mRNA Facility in Singapore

November 13, 2022

From BioNTech SE

Via GlobeNewswire

Repeat COVID-19 Infection Increases Risk Of Acute Outcomes, Long COVID Symptoms, Study Shows ↗

November 11, 2022

Via Benzinga

Is It Time To Pay Attention To This Acellular Biologic Pioneer That Says Its Clinical Trials Are Cheaper And Easier?

November 10, 2022

By Ernest Dela Aglanu, Benzinga

Via News Direct

Is It Time To Pay Attention To This Acellular Biologic Pioneer That Says Its Clinical Trials Are Cheaper And Easier?

November 10, 2022

Learn more about Organicell Regenerative Medicine, Inc.from this latest report.

Via TheNewswire.com

Europe Approves Sanofi, GSK's Beta Variant Adapted COVID Shot As Booster ↗

November 10, 2022

Via Benzinga

Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine Booster for Children 5 Through 11 Years of Age in European Union

November 10, 2022

From BioNTech SE

Via GlobeNewswire

2 Top Healthcare Stocks to Buy Right Now ↗

November 10, 2022

These two dividend stocks offer 3%-plus dividend yields that are secure.

Via The Motley Fool

< Previous 1 2

...

23 24 25 26 27 28 29 30 31

...

71 72 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.